Pyxis Oncology (NASDAQ:PYXS) Now Covered by Analysts at Stephens

Equities researchers at Stephens started coverage on shares of Pyxis Oncology (NASDAQ:PYXS) in a research report issued on Friday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $13.00 price target on the stock. Stephens’ price target would indicate a potential upside of 229.95% from the stock’s previous close.

A number of other research firms also recently commented on PYXS. Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 target price on shares of Pyxis Oncology in a report on Thursday, September 19th. Stifel Nicolaus started coverage on Pyxis Oncology in a report on Thursday, August 8th. They issued a “buy” rating and a $10.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a report on Friday, August 16th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $9.57.

Pyxis Oncology Price Performance

Shares of NASDAQ PYXS opened at $3.94 on Friday. The stock has a fifty day moving average price of $3.58 and a 200 day moving average price of $3.66. Pyxis Oncology has a 1-year low of $1.35 and a 1-year high of $6.85. The company has a market cap of $234.13 million, a PE ratio of -3.18 and a beta of 1.27.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. Analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PYXS. Fullcircle Wealth LLC acquired a new position in shares of Pyxis Oncology during the 2nd quarter worth $40,000. SG Americas Securities LLC acquired a new position in shares of Pyxis Oncology during the 3rd quarter worth $58,000. The Manufacturers Life Insurance Company acquired a new position in shares of Pyxis Oncology during the 2nd quarter worth $65,000. Cetera Advisors LLC purchased a new stake in Pyxis Oncology during the 1st quarter worth about $100,000. Finally, Schulhoff & Co. Inc. increased its position in Pyxis Oncology by 90.9% during the 2nd quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock worth $139,000 after purchasing an additional 20,000 shares in the last quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.